339 completed, 158 unknown, 128 recruiting, 111 active not recruiting. 876 Phase 3, 105 Phase 2.
Follow Cisplatin: new trials by email Literature Review of Cisplatin trials Research Report on Cisplatin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Test Shorter Duration Chemoradiation Therapy Versus Standard Duration Chemoradiation Therapy for Cervical Cancer Biospecimen Collection, Brachytherapy, Cisplatin - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 3 | Not yet recruiting | NRG Oncology | 550 | 2027-05-19 | 2026-11-10 |
| Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Cisplatin, Carboplatin, Pemetrexed - Advanced NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Goethe University | 198 | 2027-02-01 | 2026-11-17 |
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer standard EBRT+Brachytherapy, Cisplatin, Neoadjuvant chemoimmunotherapy - Locally Advanced Cervical Carcinoma | Phase 3 | Not yet recruiting | Fujian Cancer Hospital | 486 | 2027-01-01 | 2026-11-16 |
| A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer SHR-A1811 Injection, Adebrelimab Injection, Tislelizumab Injection - Non Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 436 | 2026-12-01 | 2026-10-26 |
| PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50% Pembrolizumab, Carboplatin (AUC 5), Cisplatin (75 mg/m²) - Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | German Cancer Research Center | 406 | 2026-11-30 | 2026-10-16 |
| A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC LBL-024 for Injection, Etoposide injection, Cisplatin injection - Advanced Extrapulmonary Neuroendocrine Carcinoma | Phase 3 | Not yet recruiting | Nanjing Leads Biolabs Co.,Ltd | 280 | 2026-11-16 | 2026-10-19 |
| BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy T-Bren, Dose level 1, T-bren, Dose level 2, Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin) - Urothelial Cancer, Metastatic Urothelial Cancer | Phase 3 | Recruiting | SystImmune Inc. | 520 | 2026-11-01 | 2026-11-18 |
| A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer HS-10370, Adebrelimab, Cisplatin - Carcinoma, Non-Small-Cell Lung | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 448 | 2026-10-31 | 2026-09-16 |
| ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC ASKC202, ASKC202 placebo, osimertinib placebo - EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Not yet recruiting | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 425 | 2026-10-30 | 2026-10-27 |
| A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer QLC5508, QL2107, Tislelizumab - Extensive-stage Small Cell Lung Cancer | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 556 | 2026-10-27 | 2026-10-30 |
| Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC HS-10504, platinum-based doublet chemotherapy (Pemetrexed and Cisplatin/Carboplatin) - Advanced or Metastatic NSCLC | Phase 3 | Recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 206 | 2026-10-23 | 2026-11-02 |
| A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055) Sac-TMT, Pembrolizumab and Berahyaluronidase alfa, Cisplatin - Bladder Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 400 | 2026-10-23 | 2026-11-16 |
| A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) BL-B01D1, PD-1/VEGF Bispecific Antibody, Tislelizumab - Non-squamous Non-small Cell Lung Cancer | Phase 2 / Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 166 | 2026-10-21 | 2026-11-12 |
| ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma ZG005 for Injection, Etoposide Injection, Cisplatin Injection - Neuroendocrine Carcinomas (NEC) | Phase 3 | Not yet recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 440 | 2026-10-01 | 2026-09-22 |
| Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC Becotatug Vedotin, Sintilimab, Cisplatin - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | First Affiliated Hospital of Guangxi Medical University | 266 | 2026-09-08 | 2026-11-09 |
| Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) Iza-bren, Osimertinib, Pemetrexed - Non-Small Cell Lung Cancer | Phase 3 | Recruiting | Bristol-Myers Squibb | 850 | 2026-09-08 | 2026-11-10 |
| Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma Gemcitabine, Cisplatin, Tislelizumab - Intrahepatic Cholangiocarcinoma (Icc) | Phase 3 | Not yet recruiting | Zhejiang Cancer Hospital | 140 | 2026-09-01 | 2026-10-26 |
| A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02) BL-B01D1, PD-1 monoclonal antibody, cisplatin - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 404 | 2026-09-01 | 2026-09-15 |
| Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC zoldonrasib, Placebo, pembrolizumab - NSCLC, Non-small Cell Lung Cancer | Phase 3 | Recruiting | Revolution Medicines, Inc. | 430 | 2026-08-14 | 2026-11-04 |
Showing 20 of 876. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (178) · Lung Neoplasms (63) · Uterine Cervical Neoplasms (59) · Nasopharyngeal Carcinoma (58) · Squamous Cell Carcinoma of Head and Neck (58) · Head and Neck Neoplasms (52) · Stomach Neoplasms (40) · Esophageal Neoplasms (38) · Parkinson Disease 4, Autosomal Dominant Lewy Body (38) · Esophageal Squamous Cell Carcinoma (29) · Urinary Bladder Neoplasms (29) · Small Cell Lung Carcinoma (23) · Cholangiocarcinoma (20) · Ovarian Neoplasms (19) · Carcinoma (17)
Sun Yat-sen University (48) · Merck Sharp & Dohme LLC (45) · AstraZeneca (31) · National Cancer Institute (NCI) (28) · Children's Oncology Group (23) · European Organisation for Research and Treatment of Cancer - EORTC (22) · Hoffmann-La Roche (21) · Bristol-Myers Squibb (20) · Radiation Therapy Oncology Group (17) · Gynecologic Oncology Group (16) · Eli Lilly and Company (13) · Alliance for Clinical Trials in Oncology (11) · Fudan University (11) · UNICANCER (10) · Sanofi (9)
China (336) · United States (332) · France (203) · Italy (187) · Canada (185) · United Kingdom (181) · Spain (178) · Germany (174) · South Korea (167) · Australia (155) · Japan (146) · Poland (139) · Taiwan (138) · Belgium (136) · Brazil (127)
Jun Ma, M.D. (7) · Cesare Gridelli, M.D. (6) · Francesco Perrone, M.D., Ph.D. (4) · Ciro Gallo, M.D., Ph.D (3) · Ciro Gallo, M.D., Ph.D. (3)
PMID 37139963, PMID 22689675, PMID 28837405, PMID 29584545, PMID 31150573, PMID 33358660, PMID 40501401, PMID 41343184, PMID 21444871, PMID 21840137, PMID 22551107, PMID 24982463, PMID 25057165, PMID 25624439, PMID 27567280, PMID 29924955, PMID 30213452, PMID 30548235, PMID 30633128, PMID 31401903, PMID 31420360, PMID 33337539, PMID 33492986, PMID 33661301, PMID 33684371, PMID 35997729, PMID 37158938, PMID 37419867, PMID 37465924, PMID 37505794, PMID 37699333, PMID 38383458, PMID 38642841, PMID 39230120, PMID 39369790, PMID 40311309, PMID 40373876, PMID 40532178, PMID 40966692, PMID 41747891, PMID 41887529, PMID 42176183, PMID 42579028, PMID 10481771, PMID 10882162, PMID 11181777, PMID 11391598, PMID 11464889, PMID 11560968, PMID 11762335
2023 (29), 2018 (18), U10CA180868 (18), U10CA180886 (17), 2019 (16), U10CA098543 (16), 2017 (15), 2016 (12), U10CA180820 (12), 2014 (11), 2015 (10), U10CA027469 (9), U10CA032102 (8), U10CA031946 (7), 2025 (5)